Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Uno studio su I-DXd in combinazione con atezolizumab con o senza carboplatino come induzione o mantenimento di prima linea in soggetti con carcinoma polmonare a piccole cellule in stadio esteso (IDeate-Lung03)

28 settembre 2026 aggiornato da: Daiichi Sankyo

Uno studio di fase 1b/2, multicentrico, in aperto su ifinatamab deruxtecan (I-DXd), un anticorpo-farmaco coniugato (ADC) B7-H3, in combinazione con atezolizumab con o senza carboplatino come induzione o mantenimento di prima linea, in Soggetti con carcinoma polmonare a piccole cellule in stadio esteso (ES-SCLC) (IDeate-Lung03)

This study is designed to evaluate the safety and efficacy of ifinatamab deruxtecan (I-DXd) in combination with immune checkpoint inhibitor (ICI) atezolizumab with or without carboplatin in participants with extensive stage-small cell lung cancer (ES-SCLC) in the first-line (1L) setting.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

This study consists of two parts and two cohorts: Part A (Phase 1b; Safety Run-in) and Part B (Phase 2; Dose Optimization), Cohort 1 (I-DXd in maintenance) and Cohort 2 (I-DXd in induction + maintenance).

The primary objective of this study is to evaluate the safety and tolerability of I-DXd in combination with atezolizumab with or without carboplatin by assessing treatment-emergent adverse events (TEAEs) and other safety parameters which will inform optimal dose selection of I-DXd in the combination regimens (Dose Optimization Part B) of this study.

Tipo di studio

Interventistico

Iscrizione (Stimato)

123

Fase

  • Fase 2
  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

      • Lille, Francia, 59037
        • Reclutamento
        • Hopital Albert Calmette - Chu Lille
        • Contatto:
          • Principal Investigator
      • Lyon, Francia, 69008
        • Reclutamento
        • Centre Léon Bérard
        • Contatto:
          • Principal Investigator
      • Marseille, Francia, 13005
        • Reclutamento
        • Hôpital de la Timone
        • Contatto:
          • Principal Investigator
      • Paris, Francia, 75005
        • Reclutamento
        • Institut Curie - Site de Paris
        • Contatto:
          • Principal Investigator
      • Paris, Francia, 75020
        • Reclutamento
        • Hopital Tenon
        • Contatto:
          • Principal Investigator
      • Rennes, Francia, 35000
        • Reclutamento
        • Chu Rennes - Hopital Pontchaillou
        • Contatto:
          • Principal Investigator
      • Saint-Herblain, Francia, 44805
        • Reclutamento
        • CHU Nantes - Hôpital Guillaume et René Laënnec
        • Contatto:
          • Principal Investigator
      • Suresnes, Francia, 92151
        • Reclutamento
        • Hôpital Foch
        • Contatto:
          • Principal Investigator
      • Villejuif, Francia, 94805
        • Non ancora reclutamento
        • Institut Gustave Roussy
        • Contatto:
          • Principal Investigator
      • Himeji-shi, Giappone, 670-8520
        • Reclutamento
        • NHO Himeji Medical Center
      • Hirakata-shi, Giappone, 573-1191
        • Reclutamento
        • Kansai Medical University Hospital
        • Contatto:
          • Principal Investigator
      • Kashiwa, Giappone, 277-8577
        • Reclutamento
        • National Cancer Center Hospital East
        • Contatto:
          • Principal Investigator
      • Kumamoto, Giappone, 861-4193
        • Reclutamento
        • Social Welfare Organization Saiseikai Imperial Gift Foundation, Inc. Saiseikai Kumamoto Hospital
        • Contatto:
          • Principal Investigator
      • Kōtoku, Giappone, 135-8550
        • Reclutamento
        • The Cancer Institute Hospital of Jfcr
        • Contatto:
          • Principal Investigator
      • Nagaizumi-cho, Giappone, 411-8777
        • Reclutamento
        • Shizuoka Cancer Center
        • Contatto:
          • Principal Investigator
      • Niigata, Giappone, 951-8566
        • Reclutamento
        • Niigata Cancer Center Hospital
        • Contatto:
          • Principal Investigator
      • Okayama, Giappone, 700-8558
        • Reclutamento
        • Okayama University Hospital
        • Contatto:
          • Principal Investigator
      • Tokushima, Giappone, 770-8503
        • Reclutamento
        • Tokushima University Hospital
      • Toyoake-shi, Giappone, 470-1192
        • Reclutamento
        • Fujita Health University Hospital
      • Ōsaka-sayama, Giappone, 589-8511
        • Reclutamento
        • Kindai University Hospital
        • Contatto:
          • Principal Investigator
      • Barcelona, Spagna, 08036
        • Reclutamento
        • Hospital Clinic de Barcelona
        • Contatto:
          • Principal Investigator
      • Barcelona, Spagna, 8035
        • Reclutamento
        • Hospital Universitari Vall D'Hebron
        • Contatto:
          • Principal Investigator
      • Girona, Spagna, 17007
        • Reclutamento
        • Ico Girona - Hospital Universitari de Girona Dr Josep Trueta
        • Contatto:
          • Principal Investigator
      • L'Hospitalet de Llobregat, Spagna, 08908
        • Reclutamento
        • ICO l'Hospitalet - Hospital Duran i Reynals
        • Contatto:
          • Principal Investigator
      • Madrid, Spagna, 28041
        • Reclutamento
        • Hospital Universitario 12 de Octubre
        • Contatto:
          • Principal Investigator
      • Madrid, Spagna, 28007
        • Reclutamento
        • Hospital General Universitario Gregorio Marañon
        • Contatto:
          • Principal Investigator
      • Madrid, Spagna, 28034
        • Reclutamento
        • Hospital Universitario Ramon Y Cajal
        • Contatto:
          • Principal Investigator
      • Madrid, Spagna, 28223
        • Reclutamento
        • Next Madrid
        • Contatto:
          • Principal Investigator
      • Málaga, Spagna, 29010
        • Reclutamento
        • Hospital Regional Universitario de Malaga
        • Contatto:
          • Principal Investigator
      • Seville, Spagna, 41009
        • Reclutamento
        • Hospital Universitario Virgen Macarena
        • Contatto:
          • Principal Investigator
      • Seville, Spagna, 41013
        • Reclutamento
        • Hospital Universitario Virgen Del Rocio
        • Contatto:
          • Principal Investigator
      • Vigo, Spagna, 36312
        • Reclutamento
        • Hospital Alvaro Cunqueiro
        • Contatto:
          • Principal Investigator
    • Alabama
      • Birmingham, Alabama, Stati Uniti, 35233
        • Reclutamento
        • University of Alabama -Birmingham
        • Contatto:
          • Principal Investigator
    • Arizona
      • Phoenix, Arizona, Stati Uniti, 85054
        • Reclutamento
        • Mayo Clinic Arizona
        • Contatto:
          • Principal Investigator
    • California
      • Los Angeles, California, Stati Uniti, 90095
        • Non ancora reclutamento
        • David Geffen School of Medicine
        • Contatto:
          • Principal Investigator
      • Newport Beach, California, Stati Uniti, 92663
        • Reclutamento
        • Hoag Memorial Hospital Presbyterian
        • Contatto:
          • Principal Investigator
    • Florida
      • Jacksonville, Florida, Stati Uniti, 32224
        • Reclutamento
        • Mayo Clinic-Jacksonville
        • Contatto:
          • Principal Investigator
      • Orlando, Florida, Stati Uniti, 32804
        • Reclutamento
        • Advent Health Orlando
        • Contatto:
          • Principal Investigator
      • Tampa, Florida, Stati Uniti, 33612
        • Reclutamento
        • Moffitt Cancer Center
    • Illinois
      • Chicago, Illinois, Stati Uniti, 60611
        • Reclutamento
        • Robert H. Lurie Comprehensive Cancer Center of Northwestern University
        • Contatto:
          • Principal Investigator
    • Michigan
      • Detroit, Michigan, Stati Uniti, 48202
        • Attivo, non reclutante
        • Henry Ford Hospital
    • Minnesota
      • Minneapolis, Minnesota, Stati Uniti, 55455
        • Reclutamento
        • Regents of the University of Minnesota
        • Contatto:
          • Principal Investigator
      • Rochester, Minnesota, Stati Uniti, 55905
        • Reclutamento
        • Mayo Clinic
        • Contatto:
          • Principal Investigator
    • New Hampshire
      • Lebanon, New Hampshire, Stati Uniti, 03766
        • Reclutamento
        • Dartmouth-Hitchcock Medical Center
        • Contatto:
          • Principal Investigator
    • New Jersey
      • East Brunswick, New Jersey, Stati Uniti, 08816
        • Reclutamento
        • Astera Cancer Care
      • Hackensack, New Jersey, Stati Uniti, 07601
        • Reclutamento
        • John Theurer Cancer Center At Hackensack Umc
        • Contatto:
          • Principal Investigator
    • New York
      • Mineola, New York, Stati Uniti, 11501
        • Reclutamento
        • NYU Langone Hospital - Long Island
        • Contatto:
          • Principal Investigator
      • Mineola, New York, Stati Uniti, 11501
        • Reclutamento
        • New York University Cancer Center - Laura and Isaac Perlmutter Cancer Center At Nyu Langone
        • Contatto:
          • Principal Investigator
      • New York, New York, Stati Uniti, 10021
        • Reclutamento
        • Memorial Sloan Kettering Cancer Center
        • Contatto:
          • Principal Investigator
      • New York, New York, Stati Uniti, 10461
        • Reclutamento
        • Montefiore Medical Center
      • New York, New York, Stati Uniti, 10032
        • Reclutamento
        • Columbia University Hervert Irving Comprehensive Cancer Center
        • Contatto:
          • Principal Investigator
    • Pennsylvania
      • Lancaster, Pennsylvania, Stati Uniti, 17601
        • Reclutamento
        • Lancaster General Hospital - Ann B Barshinger Cancer Institute
      • Philadelphia, Pennsylvania, Stati Uniti, 19104
        • Reclutamento
        • University of Pennsylvania, Abramson Cancer Center
      • Philadelphia, Pennsylvania, Stati Uniti, 19107
        • Reclutamento
        • Thomas Jefferson University Hospital - Central
        • Contatto:
          • Principal Investigator
    • Tennessee
      • Nashville, Tennessee, Stati Uniti, 37203
        • Reclutamento
        • Scri Oncology Partners
        • Contatto:
          • Principal Investigator
    • Virginia
      • Fairfax, Virginia, Stati Uniti, 22031
        • Reclutamento
        • Next Virginia
        • Contatto:
          • Principal Investigator
    • Washington
      • Vancouver, Washington, Stati Uniti, 98684
        • Reclutamento
        • Northwest Cancer Specialists, P.C.-Vancouver
        • Contatto:
          • Principal Investigator
    • Wisconsin
      • Milwaukee, Wisconsin, Stati Uniti, 53226
        • Reclutamento
        • Medical College of Wisconsin
        • Contatto:
          • Principal Investigator

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

A full list of inclusion/exclusion criteria are available in the protocol.

Inclusion Criteria

Participants must meet all of the following criteria to be eligible for enrollment into the study:

  1. Sign and date the informed consent form (ICF), prior to the start of any study-specific qualification procedures.

  2. Adults ≥18 years or the minimum legal adult age (whichever is greater) at the time the ICF is signed.

  3. Has histologically or cytologically confirmed diagnosis of ES-SCLC who will require first-line (IL) therapy.

  4. For Cohort 1, participant has received 4 cycles of 1L induction therapy with carboplatin, etoposide, and atezolizumab for ES-SCLC with ongoing CR PR, CR, or SD per RECIST v1.1 assessed by the investigator.

    For Cohort 2, participant has received no prior treatment for ES-SCLC.

  5. For Cohort 2, participant has at least one measurable lesion according to RECIST v1.1 on computed tomography (CT) or magnetic resonance imaging (MRI) as assessed by the investigator.

  6. For Cohort 2, participant must have at least one lesion, amenable to core biopsy, and must consent to provide a pretreatment biopsy tissue sample and on-treatment biopsy.

  7. Has ECOG PS of ≤1 (assessed within 7 days before enrollment/randomization).

  8. Has adequate organ and bone marrow function within 7 days before the start of study treatment as specified in the study protocol.

  9. A female subject of childbearing potential (POCBP) is eligible to participate if the following conditions are met:

    1. Subject is not pregnant as confirmed by highly sensitive pregnancy test during Screening (within 3 days prior to enrollment/randomization)
    2. Subject does not breastfeed during the treatment period and for at least 8/5/6 months after last dose of I-DXd/atezolizumab/carboplatin, respectively.
    3. Subject agrees to adhere to a contraceptive method that is highly effective and agrees not to donate eggs (ova, oocytes) to others or freeze/store eggs during the treatment period and for at least the time needed to eliminate each study drug after the last dose. The length of time required to continue contraception and avoid donating/freezing eggs after last dose for I-DXd/atezolizumab/carboplatin is 8/5/6 months, respectively. Preservation of eggs may be considered prior to first dose of study drug.
  10. A male subject capable of producing sperm is eligible to participate if he agrees to the following during the intervention period and for at least the time needed to eliminate each study drug. The length of time required to continue contraception and avoid donating sperm after last dose for I-DXd/atezolizumab/carboplatin is 6/5/6 months, respectively.

    1. Avoid donating sperm.
    2. Adhere to either of the contraception methods: true abstinence from penile-vaginal intercourse or uses a penile/external condom when having penile-vaginal intercourse with a non-subject of childbearing potential plus partner use of an additional contraceptive method.
  11. Is willing and able to comply with scheduled visits, drug administration plan, laboratory tests, other study procedures, and study restrictions.

Exclusion Criteria

Participants who meet any of the following criteria will be disqualified from entering the study:

  1. Has received prior treatment with orlotamab, enoblituzumab, or other B7-H3 targeted agents, including I-DXd.
  2. Prior discontinuation of an ADC that consists of an exatecan derivative (eg, trastuzumab deruxtecan) due to treatment-related toxicities.
  3. Has received prior treatment with CD137 agonists or ICIs, including anti-cytotoxic T-cell lymphocyte-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies, except for atezolizumab for Cohort 1.
  4. Has inadequate washout period before enrollment/randomization as specified in the study protocol.
  5. Has any of the following within the past 6 months: cerebrovascular accident, transient ischemic attack, or another arterial thromboembolic event.
  6. Has clinically active brain metastases, spinal cord compression, or leptomeningeal carcinomatosis, defined as untreated and symptomatic, or requiring therapy with steroids or anticonvulsants to control associated symptoms.
  7. Has clinically significant corneal disease.
  8. Has uncontrolled or significant cardiovascular disease,.
  9. Has history of (non-infectious) ILD/pneumonitis that required corticosteroids, current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging at Screening.
  10. Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses
  11. Is on chronic steroid treatment (dose of 10 mg daily or more prednisone equivalent), except for low-dose inhaled steroids (for asthma/chronic obstructive pulmonary disease, topical steroids (for mild skin conditions), or intra-articular steroid injections.
  12. Has history of malignancy other than SCLC within the 5 years prior to randomization/enrollment, except adequately resected non-melanoma skin cancer, curatively treated in situ disease, superficial gastrointestinal tract tumors, and non-muscle invasive bladder cancer curatively resected by endoscopic surgery.
  13. Has history of allogeneic bone marrow, stem cell, or solid organ transplant.
  14. Has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to NCI-CTCAE V5.0, Grade ≤1 or baseline.
  15. Has history of hypersensitivity to the drug substances, inactive ingredients in the drug product or severe hypersensitivity reactions to other monoclonal antibodies.
  16. Has evidence of ongoing uncontrolled systemic bacterial, fungal, or viral infection.
  17. Has active or uncontrolled human immunodeficiency virus (HIV) infection.
  18. Has active or uncontrolled hepatitis B or C virus (HBV or HCV) infection.
  19. Has history of autoimmune disease.
  20. Has any evidence of severe or uncontrolled systemic diseases.
  21. Has received a live vaccine within 30 days prior to the first dose of study drug.
  22. Is a female who is pregnant or breastfeeding or planning to become pregnant.
  23. Has prior or ongoing clinically relevant illness, medical condition, surgical history, physical finding, or laboratory abnormality that, in the investigator's opinion, could affect the safety of the participant; alter the absorption, distribution, metabolism, or excretion of the study drug; or confound the assessment of study results.
  24. Has psychological, social, familial, or logistical factors that would prevent regular follow-up

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Cohort 1, Part A: Maintenance Only (I-DXd 12 mg/kg)

Part A (Safety Run-in): Participants who must have received 4 cycles of 1L induction standard of care (SoC) therapy with best overall response of CR, PR, or SD will receive maintenance therapy only. Maintenance therapy consisting of I-DXd 12 mg/kg (or a lower dose based on data for I-DXd collected during the study) + atezolizumab 1200 mg IV Q3W.

A 5-day surveillance period between each of the first 3 participants (up to a maximum of 9 participants) dosed is included as a safety measure.

Intravenous administration

Altri nomi:
  • I-DXd

Intravenous administration

Sperimentale: Cohort 2, Part A: Induction + Maintenance (I-DXd 8 mg/kg)

Part A (Safety Run-in): Participants who are treatment-naive, newly diagnosed with ES-SCLC will receive 4 cycles of 1L I-DXd induction therapy (8 mg/kg IV Q3W) + atezolizumab (1200 mg IV Q3W) + carboplatin (AUC 5 mg/ml×min IV Q3W) followed by maintenance therapy. Maintenance therapy consisting of I-DXd 8 mg/kg (or a lower dose based on data for I-DXd collected during the study) + atezolizumab 1200 mg IV Q3W.

Intravenous administration

Altri nomi:
  • I-DXd

Intravenous administration

Intravenous administration

Sperimentale: Cohort 2, Part A: Induction + Maintenance (I-DXd 12 mg/kg)

Part A (Safety Run-in): Participants who are treatment-naive, newly diagnosed with ES-SCLC will receive 4 cycles of 1L I-DXd induction therapy (12 mg/kg IV Q3W) + atezolizumab (1200 mg IV Q3W) + carboplatin (AUC 5 mg/ml×min IV Q3W) followed by maintenance therapy. Maintenance therapy consisting of I-DXd 12 mg/kg (or a lower dose based on data for I-DXd collected during the study) + atezolizumab 1200 mg IV Q3W.

Intravenous administration

Altri nomi:
  • I-DXd

Intravenous administration

Intravenous administration

Sperimentale: Cohort 1, Part B: Maintenance (I-DXd 8 mg/kg)

Part B: Participants who must have received 4 cycles of 1L induction standard of care (SoC) therapy with best overall response of CR, PR, or SD will receive maintenance therapy only starting at Cycle 1 Day 1. Maintenance therapy consisting of I-DXd 8 mg/kg (or a lower dose based on data for I-DXd collected during the study) + atezolizumab 1200 mg IV Q3W

Intravenous administration

Altri nomi:
  • I-DXd

Intravenous administration

Sperimentale: Cohort 1, Part B: Maintenance (I-DXd 12 mg/kg)

Part B: Participants who must have received 4 cycles of 1L induction standard of care (SoC) therapy with best overall response of CR, PR, or SD will receive maintenance therapy only starting at Cycle 1 Day 1. Maintenance therapy consisting of I-DXd 12 mg/kg (or a lower dose based on data for I-DXd collected during the study) + atezolizumab 1200 mg IV Q3W.

Intravenous administration

Altri nomi:
  • I-DXd

Intravenous administration

Sperimentale: Cohort 2, Part B: Induction + Maintenance (I-DXd 8 mg/kg)

Participants who are treatment-naive, newly diagnosed with ES-SCLC will receive 4 cycles of 1L I-DXd induction therapy (8 mg/kg IV Q3W) + atezolizumab (1200 mg IV Q3W) + carboplatin (AUC 5 mg/ml×min IV Q3W) followed by maintenance therapy. Maintenance therapy consisting of I-DXd 8 mg/kg (or a lower dose based on data for I-DXd collected during the study) + atezolizumab 1200 mg IV Q3W.

Intravenous administration

Altri nomi:
  • I-DXd

Intravenous administration

Intravenous administration

Sperimentale: Cohort 2, Part B: Induction + Maintenance (I-DXd 12 mg/kg)

Participants who are treatment-naive, newly diagnosed with ES-SCLC will receive 4 cycles of IL I-DXd induction therapy (12 mg/kg IV Q3W) + atezolizumab (1200 mg IV Q3W) + carboplatin (AUC 5 mg/ml×minIV Q3W) followed by maintenance therapy. Maintenance therapy consisting of I-DXd 12 mg/kg (or a lower dose based on data for I-DXd collected during the study) + atezolizumab 1200 mg IV Q3W.

Intravenous administration

Altri nomi:
  • I-DXd

Intravenous administration

Intravenous administration

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Lasso di tempo
Numero di partecipanti che hanno segnalato tossicità dose-limitanti a seguito di I-DXd in combinazione con atezolizumab con o senza carboplatino (Parte A)
Lasso di tempo: Ciclo 1 Giorno 1 fino Ciclo 1 Giorno 21 (ogni ciclo dura 21 giorni)
Ciclo 1 Giorno 1 fino Ciclo 1 Giorno 21 (ogni ciclo dura 21 giorni)
Numero complessivo di partecipanti con eventi avversi emergenti dal trattamento in seguito a I-DXd in combinazione con atezolizumab con o senza carboplatino (Parte A e B)
Lasso di tempo: Baseline fino a 37 mesi
Baseline fino a 37 mesi

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Progression-free Survival As Assessed by Blinded Independent Central Review and Investigator Following I-DXd in Combination With Atezolizumab With or Without Carboplatin (Part A and B)
Lasso di tempo: From start date of study drug to the earlier date of the first objective documentation of radiographic disease progression assessed by BICR and investigator per RECIST v1.1 or death due to any cause, whichever occurs first, up to approximately 37 months

Progression-free survival is defined as the time from the enrollment/randomization date to the earlier of the dates of the first documentation of disease progression assessed by BICR and investigator per RECIST v1.1 or death due to any cause.

From start date of study drug to the earlier date of the first objective documentation of radiographic disease progression assessed by BICR and investigator per RECIST v1.1 or death due to any cause, whichever occurs first, up to approximately 37 months
Objective Response Rate Assessed by Blinded Independent Central Review and Investigator Following I-DXd in Combination With Atezolizumab With Carboplatin (Part A and B of Cohort 2 Only)
Lasso di tempo: Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 37 months

Objective response rate (ORR) is defined as proportion of subjects who achieved a best overall response of confirmed complete response (CR) or confirmed partial response (PR) per BICR and investigator according to RECIST v1.1.

Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 37 months
Duration of Response As Assessed by Blinded Independent Central Review and Investigator Following I-DXd in Combination With Atezolizumab With Carboplatin (Part A and B of Cohort 2 Only)
Lasso di tempo: From the date of first documentation of confirmed response (CR or PR) to the first documentation of objective progression or to death due to any cause, whichever occurs first, up to approximately 37 months

Duration of response (DoR) is defined as the time from the date of the first documentation of objective response (confirmed complete response [CR] or confirmed partial response [PR]) to the date of the first documentation of progressive disease (PD) or death due to any cause, whichever occurs first. The DoR will be calculated for responding participants (confirmed PR or confirmed CR) only.

From the date of first documentation of confirmed response (CR or PR) to the first documentation of objective progression or to death due to any cause, whichever occurs first, up to approximately 37 months
Disease Control Rate As Assessed by Blinded Independent Central Review and Investigator Following I-DXd in Combination With Atezolizumab With Carboplatin (Part A and B of Cohort 2 Only)
Lasso di tempo: Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 37 months

Disease control rate is defined as the proportion of participants who have achieved a best overall response of confirmed CR, confirmed PR, or SD by BICR and investigator assessment per RECIST v1.1.

Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 37 months
Clinical Benefit Rate as Assessed by Blinded Independent Central Review and Investigator Following I-DXd in Combination With Atezolizumab With Carboplatin (Part A and B of Cohort 2 Only)
Lasso di tempo: Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 37 months

Clinical benefit rate (CBR) is defined as the proportion of participants who achieved a best overall response of confirmed CR, confirmed PR, or SD lasting for at least 180 days.

Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 37 months
Time to Response As Assessed by Blinded Independent Central Review and Investigator Following I-DXd in Combination With Atezolizumab With Carboplatin (Part A and B of Cohort 2 Only)
Lasso di tempo: From the start date of study drug to the date of the first documentation of response (CR or PR) that is subsequently confirmed, up to approximately 37 months

Time to response (TTR) is defined as the time from the date of enrollment/randomization to the date of the first documentation of objective response (confirmed CR or confirmed PR) in responding subjects.

From the start date of study drug to the date of the first documentation of response (CR or PR) that is subsequently confirmed, up to approximately 37 months
Best Percentage Change in the Sum of Diameters (SoD) of Measurable Tumors As Assessed by Blinded Independent Central Review and Investigator Following I-DXd in Combination With Atezolizumab With Carboplatin (Part A and B of Cohort 2 Only)
Lasso di tempo: Baseline up to approximately 37 months

The best percentage change in SoD is defined as the percentage change in the smallest SoD from all post-baseline tumor assessments, taking as reference the baseline SoD.

Baseline up to approximately 37 months
Overall Survival Following I-DXd in Combination With Atezolizumab With or Without Carboplatin (Part A and B)
Lasso di tempo: From the start date of study drug to the date of death due to any cause, whichever occurs first, up to approximately 37 months

Time from the date of enrollment/randomization to the date of death due to any cause.

From the start date of study drug to the date of death due to any cause, whichever occurs first, up to approximately 37 months
Pharmacokinetic Parameter Maximum Serum Concentration of I-DXd
Lasso di tempo: Cycle 1 Day 1 pre-dose up to Cycle 9 (and every 2 cycles thereafter up to 37 months) Day 1 pre-dose (each cycle is 21 days)

Maximum serum concentration (Cmax) will be assessed using non-compartmental methods.

Cycle 1 Day 1 pre-dose up to Cycle 9 (and every 2 cycles thereafter up to 37 months) Day 1 pre-dose (each cycle is 21 days)
Pharmacokinetic Parameter Time to Maximum Serum Concentration of I-DXd
Lasso di tempo: Cycle 1 Day 1 pre-dose up to Cycle 9 (and every 2 cycles thereafter up to 37 months) Day 1 pre-dose (each cycle is 21 days)

Time to maximum serum concentration (Tmax) will be assessed using non-compartmental methods.

Cycle 1 Day 1 pre-dose up to Cycle 9 (and every 2 cycles thereafter up to 37 months) Day 1 pre-dose (each cycle is 21 days)
Pharmacokinetic Parameter Area Under the Concentration Curve of I-DXd
Lasso di tempo: Cycle 1 Day 1 pre-dose up to Cycle 9 (and every 2 cycles thereafter up to 37 months) Day 1 pre-dose (each cycle is 21 days)

Area under the concentration-time curve up to the last quantifiable time (AUClast) and Area under the concentration-time curve during dosing interval (AUCtau) will be assessed using non-compartmental methods.

Cycle 1 Day 1 pre-dose up to Cycle 9 (and every 2 cycles thereafter up to 37 months) Day 1 pre-dose (each cycle is 21 days)
The Number of Participants Who Are Anti-Drug Antibody (ADA)-Positive At Any Time and Who Have A Treatment-emergent Anti-Drug Antibody
Lasso di tempo: Baseline up to approximately 37 months

The ADA prevalence, which is the percentage of participants who are ADA positive at any time point (baseline or postbaseline), as well as the ADA incidence, which is the proportion of participants having treatment-emergent ADA during the study period, will be reported.

Baseline up to approximately 37 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Collaboratori

Investigatori

  • Direttore dello studio: Global Clinical Leader, Daiichi Sankyo

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

22 luglio 2024

Completamento primario (Stimato)

20 luglio 2027

Completamento dello studio (Stimato)

20 febbraio 2028

Date di iscrizione allo studio

Primo inviato

2 gennaio 2024

Primo inviato che soddisfa i criteri di controllo qualità

8 aprile 2024

Primo Inserito (Effettivo)

12 aprile 2024

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

1 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

28 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • DS7300-189
  • 2023-509629-36 (Altro identificatore: EU CT)
  • 2031240089 (Altro identificatore: JRCT)
  • 2023 (Sovvenzione/contratto NIH degli Stati Uniti)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

De-identified individual participant data (IPD) on completed studies and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/

Periodo di condivisione IPD

Completed studies that has reached a global end or completion with all data set collected and analyzed, and for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.

Criteri di accesso alla condivisione IPD

Formal request from qualified scientific and medical researchers on IPD and clinical study documents on completed clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA
  • ICF

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .